Cargando…

Treatment sequences for advanced renal cell carcinoma: A health economic assessment

OBJECTIVE: Advanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors. As new therapies emerge, interest grows in gaining a deeper understanding of treatment sequences. Recently, we developed a patient-level, discretely...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deniz, Baris, Ambavane, Apoorva, Yang, Shuo, Altincatal, Arman, Doan, Justin, Rao, Sumati, Michaelson, M. Dror
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715231/ https://www.ncbi.nlm.nih.gov/pubmed/31465470 http://dx.doi.org/10.1371/journal.pone.0215761

Ejemplares similares

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma
por: Deniz, Baris, et al.
Publicado: (2018)

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
por: McCrea, Charles, et al.
Publicado: (2018)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department
por: Ambavane, Apoorva, et al.
Publicado: (2017)

Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
por: Bonine, Nicole G, et al.
Publicado: (2017)

Correction: Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department
por: Ambavane, Apoorva, et al.
Publicado: (2018)

2814. The Impact of Novel Antibiotics on Curbing Antimicrobial Resistance and Infection Spread a Dynamic Modeling Study
por: Ambavane, Apoorva, et al.
Publicado: (2023)

The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective
por: Menzin, Joseph, et al.
Publicado: (2012)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
por: George, Daniel J., et al.
Publicado: (2019)

Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
por: DePrimo, Samuel E, et al.
Publicado: (2007)

Sequence of treatment in locally advanced and metastatic renal cell carcinoma
por: Fischer, Stefanie, et al.
Publicado: (2015)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
por: Hahn, Andrew W., et al.
Publicado: (2017)

Determinants of treatment in patients with stage IV renal cell carcinoma
por: Hollenbeak, Christopher S., et al.
Publicado: (2019)

Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?
por: Lodise, Thomas, et al.
Publicado: (2017)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
por: Cella, David, et al.
Publicado: (2014)

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps
por: Guo, Shien, et al.
Publicado: (2012)

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening
por: Phillips, Glenn A, et al.
Publicado: (2014)

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?
por: Lodise, Thomas P, et al.
Publicado: (2019)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Dementia Coding, Workup, and Treatment in the VA New England Healthcare System
por: Cho, Kelly, et al.
Publicado: (2014)

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
por: Shah, Ruchitbhai, et al.
Publicado: (2019)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

Assessment of hypercoagulability using thromboelastography predicts advanced status in renal cell carcinoma
por: Wang, Xun, et al.
Publicado: (2019)

Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
por: Liu, Jun S., et al.
Publicado: (2016)

Recent Advances in Renal Medullary Carcinoma
por: Su, Yongdong, et al.
Publicado: (2022)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Next-generation sequencing in non-muscle-invasive bladder cancer—a step towards personalized medicine for a superficial bladder tumor
por: Butterfield, Andrew, et al.
Publicado: (2017)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Papillary renal cell carcinoma and collecting duct carcinoma combination. A case report and review of synchronous renal cell carcinoma subtypes in the same kidney
por: Arık, Deniz, et al.
Publicado: (2015)

The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma
por: Shafrin, Jason, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_03dcstcq19nlhgir0u7ks6opd1